Patent US4595684A successfully refreshed from Google Patents.
US4595684A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof
Assignee: Novartis Corp
•
Filing: 1985-08-16
•
Granted: 1986-06-17
•
Expires: 2005-08-16
Abstract
Abstract A method of suppressing benzodiazepine induced sedation normally associated in the treatment of anxiety in a mammal with an anxiolytically effective amount of a benzodiazepine anti-anxiety agent, comprising the administration to said mammal an effective sedation antagonistic amount of 2-(p-methoxyphenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a pharmaceutically acceptable salt thereof.
Inventors
- 👤 Debra A. Bennett
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 20:08
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
50 words
A method of suppressing benzodiazepine induced sedation of the type normally associated in the treatment of anxiety in a mammal receiving anxiolytically effective amount of a benzodiazepine anxiolytic agent, comprising the administration to said mammal of an effective sedation antagonistic amount of 2-(p-methoxyphenyl)-pyrazolo[4,3-c]quinolin-b 3(5H)-one or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
50 words
A method of suppressing benzodiazepine induced sedation of the type normally associated in the treatment of anxiety in a mammal receiving anxiolytically effective amount of a benzodiazepine anxiolytic agent, comprising the administration to said mammal of an effective sedation antagonistic amount of 2-(p-methoxyphenyl)-pyrazolo[4,3-c]quinolin-b 3(5H)-one or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
32 words
A method according to claim 1, wherein said benzodiazepine anxiolytic agent is selected from the group consisting of diazepam, bromazepam, alprazolam, camazepam, clobazam, chlordesmethyldiazepam, clorazepate, halazepam, prazepam, lorazepam, chlorodiazepoxide, oxazepam and flurazepam.
Claim 4
Dependent Claim
11 words
A method according to claim 1 wherein said benzodiazepine is diazepam.
Claim 5
Dependent Claim
28 words
A method according to claim 1 wherein the administration of the benzodiazepine anxiolytic agent is substantially simultaneous with the administration of 2-(p-methoxyphenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one, or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
16 words
A method according to claim 4, wherein said simultaneous administration is as a unit dose form.
Claim 7
Dependent Claim
12 words
A method according to claim 5, wherein said simultaneous administration is oral.
References Cited (Backward Citations)
US4312870A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-06-16 | 1989-12-16 | 1990-06-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-06-16 | 1993-12-16 | 1994-06-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-06-16 | 1997-12-16 | 1998-06-17 | $7700.00 | Window Closed / Lapsed |